Goldman Sachs Upgrades BioNTech, Citing Major Oncology Opportunity

BioNTech US09075V1026

Shares of BioNTech advanced significantly on Friday following an upgrade from Goldman Sachs. The US investment bank now views the German biotech firm as a primary beneficiary of the next generation of cancer treatments, estimating the total market potential at over $100 billion. This positive assessment coincides with the company providing more detailed plans for its development pipeline, targeting key milestones by 2026.

In a move that shifted its stance from “Neutral” to “Buy,” Goldman Sachs highlighted BioNTech’s strategic focus in immuno-oncology and Antibody-Drug Conjugates (ADCs). Analyst Asad Haider pointed to these therapeutic approaches as among the most promising advancements in oncology, a sector the bank values in excess of $100 billion.